secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2023-04-10T23:59:59+00:00
Accession:  0001493152-23-011642
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma completes $4M private placement of common stock at $1.97/share
-------------------------------------------------------------------------------

- Sold 2,030,458 shares at $1.97 each for total proceeds of $4.0 million.
- Investors: director/co-founder Phillip Frost and Fred Hassan (Caret Group, Warburg Pincus), each investing $2.0 million.
- Net proceeds to advance preclinical/clinical antiviral programs and for working capital.
- Company preparing for Phase 2a influenza A study (CC-42344) and first-in-human COVID-19 trial (CDI-988) in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315223011642/0001493152-23-011642-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315223011642/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-011642

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer